New York-based pre-visualization boutique Edit 1 unveils state-of-the-art “inertial” motion capture, InMoCa.
New York, NY -- Pre-visualization boutique Edit1 has become the first studio in New York to offer state-of-the-art “inertial” motion capture (or as the studio refers to it -- “InMoCa”). The InMoCa technology provides tremendous advantages over more traditional “optical” motion capture.
“Like most pre-vis studios, we’ve been working with mocap for years,” says company President Michael Zimbard. “We pride ourselves on not following trends, but rather setting them, and when we learned about inertial motion capture and the impact it could have on our client’s work we knew we wanted to make the investment and be the first company in the New York market to offer it.”
Manufactured by Netherlands-based Xsens and already used extensively in Hollywood (Ted, X-Men First Class, Paul, John Carter, among others), inertial mocap offers an array of advantages over traditional mocap. One of the biggest advantages is that it doesn’t tie you to a mocap studio, but allows you the flexibility to capture performances literally anywhere – in the newly redesigned Edit 1 studio, on their beautiful outdoor patio or even onsite in an agency creative director’s office. The motion capture data is transmitted directly from the sensors on the Lycra suit into a laptop computer with no cameras, allowing for a more accurate performance capture in significantly less time.
“Not having to be tied to a greenscreen stage opens up so many creative possibilities that it almost seemed too good to be true,” Mike Donovan, Edit1’s Executive Producer, says. “This technology is changing the way we do things and offering clients more options and faster turnaround on their projects than ever imagined.”
Clients are already reaping the benefits of InMoCa. Since its incorporation into the Edit1 pipeline, the system has become an integral part of every project, including a recent series of spots for agency J. Walter Thompson, New York and pharmaceutical giant Pfizer.
“The goal behind all of our recent development is to both leverage technology to make the process better for our clients, and give our team more time to focus on the creative aspects of a job and less time negotiating technical hurdles,” Zimbard notes. “We pride ourselves as leaders in the evolution of the previs industry and InMoCa is a game-changer.”
Source: Edit 1